Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease

Trial Profile

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donanemab (Primary) ; LY 3202626 (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TRAILBLAZER-ALZ
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Aug 2019 Status changed from recruiting to active, no longer recruiting.
    • 02 Jul 2019 Planned End Date changed from 16 Sep 2021 to 12 Nov 2021.
    • 02 Jul 2019 Planned primary completion date changed from 15 Oct 2020 to 11 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top